Cancer Therapy News and Research

RSS

LC-MRM could provide better understanding of multiple myeloma drug resistance

12 Sep 2011

Moffitt researchers employ LC-MRM to detect acquired multiple myeloma drug resistance

"Acquired drug resistance" (ADR) is a major problem encountered in treating some forms of cancer. The ability to monitor the proteins involved in drug resistance has been a hurdle facing cancer researchers. However, a team of researchers at Moffitt Cancer Center, and colleagues, are pioneering promising research utilizing a monitoring technology that could provide a better understanding of ADR and assist in clinical decision-making for developing individualized patient treatments for multiple myeloma.

9 Sep 2011

Landmark discovery in rapid spread of PRL-3 oncoprotein associated aggressive cancers

Scientists at A*STAR's Institute of Molecular and Cell Biology (IMCB) have made a landmark discovery in the battle against the rapid spread of aggressive cancers associated with PRL-3 oncoprotein.

9 Sep 2011

Study identifies genes never before linked to antibiotic resistance in enterococci

An analysis of the genome of a superbug has yielded crucial, novel information that could aid efforts to counteract the bacterium's resistance to an antibiotic of last resort.

9 Sep 2011

Studies examine overuse of scans in determining status of prostate cancer

During Prostate Cancer Awareness Month, researchers will publish the findings of two studies examining the use, or overuse, of scans in determining the status or level of a patient's prostate cancer after diagnosis. "Typically, patients with an elevated PSA level undergo a prostate biopsy to confirm the presence of cancer.

8 Sep 2011

SFDA approves MedWaves' AveCure microwave coagulation-ablation system for cancer

MedWaves' AveCure microwave coagulation-ablation (MWA) system uses microwave energy to volumetrically coagulate-ablate (destroy) soft-tissue lesions safely, effectively, precisely and with repeatability.

7 Sep 2011

Leading cancer journals publish OncoGenex's custirsen pre-clinical and Phase II study data

OncoGenex Pharmaceuticals, Inc. announced today that data from two studies, a Phase II clinical study and a pre-clinical study, evaluating the investigational compound custirsen, were published in the September issues of the journals Clinical Cancer Research and Cancer Research.

7 Sep 2011

C. sporogenes bacterium could be used as vehicle to deliver drugs in frontline cancer therapy

A bacterial strain that specifically targets tumours could soon be used as a vehicle to deliver drugs in frontline cancer therapy. The strain is expected to be tested in cancer patients in 2013 says a scientist at the Society for General Microbiology's Autumn Conference at the University of York.

5 Sep 2011

Researchers discover group of mutations involved in T-cell acute lymphoblastic leukemia

An international team of researchers has found a group of mutations involved in T-cell acute lymphoblastic leukemia (T-ALL), and showed that a group of certain drugs, already in clinical use to treat other diseases, can eliminate the cells carrying these mutations.

5 Sep 2011

Researchers discover mechanism of low-dose LDN on cell proliferative-related disorders

Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered the mechanism by which a low dose of the opioid antagonist naltrexone (LDN), an agent used clinically to treat cancer and autoimmune diseases, exerts a profound inhibitory effect on cell proliferation.

3 Sep 2011

SWOG selects four cancer researchers for 2011 Young Investigator Training Course

SWOG has selected four talented, early-career researchers for its 2011 Young Investigator Training Course. These four will attend a three-day workshop September 19 - 21 in Seattle, Wash., for intensive training in how to design and conduct cancer clinical trials.

3 Sep 2011

Mayo Clinic and IC-MedTech enter collaborative research agreement with Summa Health System

Researchers from the Mayo Clinic and representatives from IC-MedTech signed a collaborative research agreement with Summa Health System to study the usage of Apatone, a proprietary combination of Vitamin-C and Vitamin-K3.

2 Sep 2011

ACS' Commission on Cancer releases new standards to directly address patient concerns

A patient-centered approach is at the forefront of new accreditation standards for hospital cancer programs released today by the Commission on Cancer (CoC) of the American College of Surgeons.

2 Sep 2011

FDA approves crizotinib for treatment of ALK-positive lung cancer

In a major triumph for personalized medicine, the FDA approved the drug crizotinib for use with the lung cancer type known as ALK-positive.

2 Sep 2011

Engineered virus shows promise in cancer therapy via bloodstream

Scientists have engineered a virus that when injected into the blood, can selectively target cancer cells throughout the body. The virus attacked only tumours, leaving the healthy tissue alone, in a small trial on 23 patients, according to the journal Nature.

2 Sep 2011

Prostate cancer linked to pesticides: Study

Researchers at the University of Southern California (USC) have found an increased prevalence of prostate cancer among older men exposed to certain pesticides in Central Valley neighborhoods.

31 Aug 2011

Research shows numerous health benefits of Modified Citrus Pectin

New research published in the journal BMC Complementary and Alternative Medicine shows Modified Citrus Pectin (MCP) packs a powerful immune punch.

31 Aug 2011

Viewpoints: States' anti-abortion laws; unproven cancer therapy; paying for retirees' health benefits

Since last year, 13 states, including Kansas, have enacted laws banning insurance coverage of abortion in the health insurance exchanges created by the federal health care reform law. Some states have gone even further, aggressively restricting abortion coverage even in private insurance plans sold outside the exchanges. ... These cases, some of which are being appealed, are testing whether the antiabortion movement will get its way. It shouldn't.

31 Aug 2011

Biophysicists discover how to turn body's own resistance to radiation treatment on and off

Radiation can make cancer cells resistant to radio- and chemotherapy. University of Oslo researchers have now figured out how resistance can be switched on and off.

30 Aug 2011

Ecstasy redesigned for use against blood cancer

The illicit drug ecstasy has been redesigned by researchers at the University of WA for use in treatment of blood cancers.

30 Aug 2011

Cancer Therapy News and Research

LC-MRM could provide better understanding of multiple myeloma drug resistance

Moffitt researchers employ LC-MRM to detect acquired multiple myeloma drug resistance

Landmark discovery in rapid spread of PRL-3 oncoprotein associated aggressive cancers

Study identifies genes never before linked to antibiotic resistance in enterococci

Studies examine overuse of scans in determining status of prostate cancer

SFDA approves MedWaves' AveCure microwave coagulation-ablation system for cancer

Leading cancer journals publish OncoGenex's custirsen pre-clinical and Phase II study data

C. sporogenes bacterium could be used as vehicle to deliver drugs in frontline cancer therapy

Researchers discover group of mutations involved in T-cell acute lymphoblastic leukemia

Researchers discover mechanism of low-dose LDN on cell proliferative-related disorders

SWOG selects four cancer researchers for 2011 Young Investigator Training Course

Mayo Clinic and IC-MedTech enter collaborative research agreement with Summa Health System

ACS' Commission on Cancer releases new standards to directly address patient concerns

FDA approves crizotinib for treatment of ALK-positive lung cancer

Engineered virus shows promise in cancer therapy via bloodstream

Prostate cancer linked to pesticides: Study

Research shows numerous health benefits of Modified Citrus Pectin

Viewpoints: States' anti-abortion laws; unproven cancer therapy; paying for retirees' health benefits

Biophysicists discover how to turn body's own resistance to radiation treatment on and off

Ecstasy redesigned for use against blood cancer

Your guide to microplate readers for cancer research eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News